CHF Solutions to Exhibit at the ESC Congress 2017 in Barcelona, Spain, August 26-30, 2017

August 24, 2017

CHF Solutions to Exhibit at the ESC Congress 2017 in Barcelona, Spain, August 26-30, 2017 15.2 KB

EDEN PRAIRIE, Minn., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today it will be exhibiting at the European Society of Cardiology, ESC Congress 2017 meeting in Barcelona, Spain, from August 26 through August 30, 2017 in the Emerging Technology Showcase Area at booth F170. The ESC Congress is the world's largest cardiovascular congress with over 500 experts' sessions and more than 4,500 abstracts contributing to the advancement of cardiovascular medicine worldwide. The Company will be meeting with both cardiology key opinion leaders and potential product distributors during the Congress .

About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the Company's expectations about meeting with cardiology key opinion leaders and potential product distributors during the Congress. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:



Claudia Napal Drayton

Chief Financial Officer

CHF Solutions, Inc.

T: +1-952-345-4205



- or -



Bret Shapiro

Managing Partner

CORE IR

516 222 2560

brets@coreir.com

www.coreir.com



Investor Relations

CHF Solutions, Inc.ir@chf-solutions.com